[
  {
    "question": "Patient presented with right arm weakness slowly progressive for 5 years then became static, involving multiple muscles and sparing brachioradialis, deny pain or trauma, what is expected to be found?",
    "option_a": "Segmental atrophy on spinal MRI",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with slowly progressive right arm weakness over 5 years that then becomes static, with multiple muscle groups involved but sparing the brachioradialis\u2014a classic pattern seen in focal motor neuron disorders such as Hirayama disease (monomelic amyotrophy). The selective involvement of certain muscle groups is a key clinical clue. Hirayama disease is thought to result from a dynamic compression of the lower cervical spinal cord during neck flexion. This repeated or sustained cord compression leads to ischemic changes and focal atrophy of the anterior horn cells, causing segmental cord atrophy. Modern imaging with flexion MRI frequently demonstrates anterior displacement of the posterior dural sac and localized cord thinning. Patients typically present in adolescence or young adulthood with unilateral upper limb weakness and atrophy that stabilizes after a period of progression. The relative sparing of the brachioradialis muscle leads to an 'oblique atrophy' pattern, which differentiates it from other motor neuron diseases like ALS that are relentlessly progressive. The workup includes a high\u2010resolution cervical spine MRI\u2014particularly with the neck in flexion\u2014to visualize cord morphology and dynamic dural changes. Differential diagnoses include ALS (which generally shows a relentlessly progressive course), cervical spondylotic myelopathy, and inflammatory myelopathies. Electrophysiological studies can further help distinguish a lower motor neuron process. The mainstay of treatment is conservative management. A cervical collar to prevent neck flexion is recommended to reduce ongoing microtrauma to the cord. Physical therapy can aid in maintaining function. In pregnancy and lactation, non-pharmacologic interventions like cervical immobilization remain safe, while systemic pharmacotherapy is usually not indicated. Option A \u2013 'Segmental atrophy on spinal MRI' \u2013 is correct, as imaging typically reveals focal atrophy of the lower cervical cord with dynamic changes that support the diagnosis of Hirayama disease. Alternate options (not listed) might have included other imaging findings or EMG changes, but the segmental atrophy is the expected feature. \u2022 Unilateral upper\u2010limb atrophy that stabilizes after a period of progression is characteristic for Hirayama disease. \u2022 The preservation of brachioradialis muscle function creates the 'oblique atrophy' pattern. \u2022 Flexion MRI of the cervical spine is essential for diagnosis. Recent studies emphasize the utility of dynamic, flexion MRI in diagnosing Hirayama disease. There is growing consensus on conservative management with a cervical collar as the first\u2010line intervention, with further research exploring the long-term outcomes in such patients.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 40-year-old female had proximal muscle weakness and progressive dysphagia. Exam she has weak cough and edematous eyes, what is the treatment? (Long scenario on weakness description and only mentioned 1 symptom of myopathy which was the edematous eyes) (Case of dermatomyositis)",
    "option_a": "Plasmaparesis",
    "option_b": "IV methylprednisolone",
    "option_c": "IVIG",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with slowly progressive right arm weakness over 5 years that then becomes static, with multiple muscle groups involved but sparing the brachioradialis\u2014a classic pattern seen in focal motor neuron disorders such as Hirayama disease (monomelic amyotrophy). The selective involvement of certain muscle groups is a key clinical clue. Hirayama disease is thought to result from a dynamic compression of the lower cervical spinal cord during neck flexion. This repeated or sustained cord compression leads to ischemic changes and focal atrophy of the anterior horn cells, causing segmental cord atrophy. Modern imaging with flexion MRI frequently demonstrates anterior displacement of the posterior dural sac and localized cord thinning. Patients typically present in adolescence or young adulthood with unilateral upper limb weakness and atrophy that stabilizes after a period of progression. The relative sparing of the brachioradialis muscle leads to an 'oblique atrophy' pattern, which differentiates it from other motor neuron diseases like ALS that are relentlessly progressive. The workup includes a high\u2010resolution cervical spine MRI\u2014particularly with the neck in flexion\u2014to visualize cord morphology and dynamic dural changes. Differential diagnoses include ALS (which generally shows a relentlessly progressive course), cervical spondylotic myelopathy, and inflammatory myelopathies. Electrophysiological studies can further help distinguish a lower motor neuron process. The mainstay of treatment is conservative management. A cervical collar to prevent neck flexion is recommended to reduce ongoing microtrauma to the cord. Physical therapy can aid in maintaining function. In pregnancy and lactation, non-pharmacologic interventions like cervical immobilization remain safe, while systemic pharmacotherapy is usually not indicated. Option A \u2013 'Segmental atrophy on spinal MRI' \u2013 is correct, as imaging typically reveals focal atrophy of the lower cervical cord with dynamic changes that support the diagnosis of Hirayama disease. Alternate options (not listed) might have included other imaging findings or EMG changes, but the segmental atrophy is the expected feature. \u2022 Unilateral upper\u2010limb atrophy that stabilizes after a period of progression is characteristic for Hirayama disease. \u2022 The preservation of brachioradialis muscle function creates the 'oblique atrophy' pattern. \u2022 Flexion MRI of the cervical spine is essential for diagnosis. Recent studies emphasize the utility of dynamic, flexion MRI in diagnosing Hirayama disease. There is growing consensus on conservative management with a cervical collar as the first\u2010line intervention, with further research exploring the long-term outcomes in such patients.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "(Same scenario) Patient with weakness symptoms suggestive of (Anti- Musk MG) was on Mycophenolic acid and steroid with no benefit switched to Azathioprine and developed hepatotoxicity, what to test before initiating treatment of the above chosen medication?",
    "option_a": "Hepatitis B screening",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with slowly progressive right arm weakness over 5 years that then becomes static, with multiple muscle groups involved but sparing the brachioradialis\u2014a classic pattern seen in focal motor neuron disorders such as Hirayama disease (monomelic amyotrophy). The selective involvement of certain muscle groups is a key clinical clue. Hirayama disease is thought to result from a dynamic compression of the lower cervical spinal cord during neck flexion. This repeated or sustained cord compression leads to ischemic changes and focal atrophy of the anterior horn cells, causing segmental cord atrophy. Modern imaging with flexion MRI frequently demonstrates anterior displacement of the posterior dural sac and localized cord thinning. Patients typically present in adolescence or young adulthood with unilateral upper limb weakness and atrophy that stabilizes after a period of progression. The relative sparing of the brachioradialis muscle leads to an 'oblique atrophy' pattern, which differentiates it from other motor neuron diseases like ALS that are relentlessly progressive. The workup includes a high\u2010resolution cervical spine MRI\u2014particularly with the neck in flexion\u2014to visualize cord morphology and dynamic dural changes. Differential diagnoses include ALS (which generally shows a relentlessly progressive course), cervical spondylotic myelopathy, and inflammatory myelopathies. Electrophysiological studies can further help distinguish a lower motor neuron process. The mainstay of treatment is conservative management. A cervical collar to prevent neck flexion is recommended to reduce ongoing microtrauma to the cord. Physical therapy can aid in maintaining function. In pregnancy and lactation, non-pharmacologic interventions like cervical immobilization remain safe, while systemic pharmacotherapy is usually not indicated. Option A \u2013 'Segmental atrophy on spinal MRI' \u2013 is correct, as imaging typically reveals focal atrophy of the lower cervical cord with dynamic changes that support the diagnosis of Hirayama disease. Alternate options (not listed) might have included other imaging findings or EMG changes, but the segmental atrophy is the expected feature. \u2022 Unilateral upper\u2010limb atrophy that stabilizes after a period of progression is characteristic for Hirayama disease. \u2022 The preservation of brachioradialis muscle function creates the 'oblique atrophy' pattern. \u2022 Flexion MRI of the cervical spine is essential for diagnosis. Recent studies emphasize the utility of dynamic, flexion MRI in diagnosing Hirayama disease. There is growing consensus on conservative management with a cervical collar as the first\u2010line intervention, with further research exploring the long-term outcomes in such patients.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient progressed rapidly to quadriplegic and got intubated, he is awake and following commands with ocular movement, MRI normal, what do next?",
    "option_a": "NCS/RNS",
    "option_b": "Cerebral angiography",
    "option_c": "Toxicology",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "When a patient rapidly develops quadriplegia with respiratory failure yet remains awake and able to follow commands using only ocular movements, the differential shifts toward a neuromuscular disorder rather than a primary central nervous system lesion. A normal brain MRI supports this, making disorders such as Guillain\u2013Barr\u00e9 syndrome or neuromuscular junction pathologies (e.g., myasthenic crisis or botulism) more likely. Nerve conduction studies (NCS) and repetitive nerve stimulation (RNS) are key electrophysiological tools that help differentiate these conditions. In conditions like Guillain\u2013Barr\u00e9 syndrome (GBS), an autoimmune-mediated attack on peripheral myelin or axons leads to conduction slowing or block. In myasthenia gravis or botulism, impaired neuromuscular transmission occurs due to antibodies against acetylcholine receptors or neurotoxins, respectively. The preservation of ocular movement with generalized paralysis is a pattern seen in these peripheral disorders. The clinical picture\u2014rapidly progressive quadriplegia requiring intubation with intact cognition and limited voluntary movement (ocular movements only)\u2014is strongly suggestive of a \u2018locked-in\u2019 type picture secondary to peripheral neuromuscular failure. In GBS, motor deficits may be severe, and respiratory compromise is common, while ocular muscles are often spared. Similarly, neuromuscular junction disorders may present with fluctuating weakness, though they often involve ocular muscles; hence, the precise diagnosis relies on electrophysiological testing. Given the normal brain MRI, further evaluation should focus on the peripheral nervous system. Electrodiagnostic studies (NCS/RNS) are performed to assess nerve conduction velocity, amplitude, and response to repetitive stimulation, which are useful in differentiating demyelinating neuropathies (such as the acute inflammatory demyelinating polyneuropathy variant of GBS) from neuromuscular junction disorders. Once the diagnosis is confirmed via electrophysiologic studies, management is tailored accordingly. For Guillain\u2013Barr\u00e9 syndrome, current guidelines recommend early treatment with intravenous immunoglobulin (IVIG) or plasmapheresis. In myasthenic crisis, management may include cholinesterase inhibitors, IVIG, or plasmapheresis. In pregnant or lactating women, IVIG and plasmapheresis are both considered safe options and are preferred as they have a well-established safety profile during these periods. Option A (NCS/RNS) is the appropriate next diagnostic step, as it investigates peripheral nerve and neuromuscular junction function. Option B (Cerebral angiography) would be used if a vascular cause such as basilar artery occlusion (the classical cause of locked\u2010in syndrome due to a pontine infarct) had a high likelihood, but a normal MRI argues against this. Option C (Toxicology) might be considered if there were a history or suspicion for toxin exposure (e.g., botulism); however, the clinical scenario and rapid progression point more toward an acute neuromuscular disorder, making electrophysiological studies the more direct next step. Option D is not provided. \u2022 In patients with profound quadriplegia but intact cognitive function, always consider neuromuscular etiologies (GBS, myasthenic crisis, or toxin-mediated paralysis) over central causes.  \u2022 A normal brain MRI in the appropriate clinical context steers the evaluation toward the peripheral nervous system.  \u2022 Early electrophysiological studies facilitate prompt diagnosis and treatment, which is critical for recovery. Recent guidelines emphasize the importance of early nerve conduction studies in suspected Guillain\u2013Barr\u00e9 syndrome to confirm the diagnosis and differentiate between demyelinating and axonal forms, which has prognostic and therapeutic implications. Additionally, in settings of myasthenic crisis, repetitive nerve stimulation helps identify decremental responses characteristic of impaired neuromuscular transmission. Both IVIG and plasmapheresis are supported by current evidence as safe and effective treatments, including in pregnant and lactating populations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 40-year-old previously healthy male developed GI symptoms, then had generalized weakness and decreased reflexes. Has bilateral ptosis and dilated pupils, what is the diagnosis?",
    "option_a": "Botulism",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Botulism is a neuroparalytic syndrome caused by ingestion (or other routes) of Clostridium botulinum toxin. The toxin blocks neuromuscular transmission, leading to a characteristic descending paralysis that often begins with cranial nerve involvement. Botulinum toxin prevents the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins at the presynaptic terminal. This blockade interrupts both voluntary and autonomic neurotransmission, which explains the combination of generalized weakness, diminished reflexes, cranial nerve deficits (ptosis), and autonomic signs (dilated pupils). A previously healthy 40\u2010year\u2010old male who develops GI symptoms (suggesting ingestion of contaminated food) followed by neurological deficits featuring generalized weakness and cranial nerve involvement (bilateral ptosis and dilated pupils) fits the classic presentation of food\u2010borne botulism. Diagnosis is primarily clinical. Laboratory confirmation may involve toxin assays on serum, stool, or food samples. Differentials include myasthenia gravis (typically fluctuating weakness without GI prodrome), Miller Fisher variant of Guillain\u2013Barr\u00e9 syndrome (which has ataxia and ophthalmoplegia but usually not dilated pupils), and other neuromuscular junction disorders. Electrophysiological studies, such as repetitive nerve stimulation, can help clarify the diagnosis. According to the **Centers for Disease Control and Prevention (CDC) 2023 guidelines**, the cornerstone of botulism management is prompt administration of **botulinum antitoxin**, which neutralizes circulating toxin but does not reverse established neuromuscular blockade. Supportive care includes respiratory monitoring and mechanical ventilation if needed. Early antitoxin administration reduces morbidity and mortality. Wound botulism requires surgical debridement and antibiotics (avoiding aminoglycosides due to neuromuscular blockade potentiation). Infant botulism management may include human-derived botulism immune globulin. Rehabilitation focuses on recovery of neuromuscular function over weeks to months. Novel therapies targeting SNARE protein restoration are under investigation but not yet standard. Option A (Botulism): Correct. The clinical presentation of bilateral ptosis, dilated pupils, descending paralysis with decreased reflexes following GI symptoms is classic for botulism. The presynaptic blockade of ACh release explains the autonomic dysfunction and flaccid paralysis.  Incorrect options (B, C, D): Although unspecified here, common differential diagnoses might include: - Guillain-Barr\u00e9 syndrome: Typically presents with ascending paralysis and preserved pupillary function; autonomic symptoms are less prominent and pupils usually reactive. - Myasthenia gravis: Characterized by fluctuating, fatigable weakness without pupillary involvement; reflexes are normal. - Lambert-Eaton myasthenic syndrome: Proximal weakness with autonomic features but usually associated with malignancy; pupils are normal. These conditions lack the combination of gastrointestinal prodrome, bilateral cranial neuropathies with dilated pupils, and descending paralysis seen in botulism. - **Descending paralysis with early cranial nerve involvement and autonomic dysfunction (dilated pupils) is a hallmark of botulism.** - **Pupillary dilation differentiates botulism from other causes of neuromuscular weakness like Guillain-Barr\u00e9 syndrome and myasthenia gravis.** - Early administration of antitoxin is critical; do not delay treatment while awaiting confirmatory tests. - Electrophysiological studies showing incremental response at high-frequency stimulation support presynaptic blockade. - Avoid aminoglycosides and other neuromuscular blocking agents that can worsen weakness. - Consider botulism in any patient with acute flaccid paralysis and autonomic signs, especially with GI symptoms or suspicious exposures. The **CDC Botulism Clinical Guidelines (2023)** state: \u201cAdministration of botulinum antitoxin as soon as possible after clinical diagnosis is associated with improved outcomes and reduced need for mechanical ventilation.\u201d They also emphasize the importance of early recognition of autonomic signs such as dilated pupils and cranial neuropathies in diagnosis. Current evidence supports supportive care as essential, with respiratory failure being the leading cause of mortality. Knowledge gaps remain regarding optimal dosing and timing of antitoxin in different botulism forms. Recent advances include improved diagnostic PCR assays for rapid toxin gene detection and research into SNARE protein-targeted therapies. Controversies persist regarding the role of antibiotics in foodborne botulism and the best approach to infant botulism management, but consensus favors supportive care and immunotherapy as mainstays.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with right hand grip weakness and numbness, 4 weeks ago had right foot drop and 1 week ago developed left foot drop that improved, what next step?",
    "option_a": "Imuran",
    "option_b": "Pulse steroid",
    "option_c": "IVIG",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with an evolving, multifocal asymmetric peripheral neuropathy\u2013\u2013initially with foot drop (right then transient left) now followed by right hand grip weakness with numbness. Such a pattern suggests an immune\u2010mediated process affecting individual nerves (i.e., a multifocal neuropathy). The differential includes variants of chronic inflammatory demyelinating polyneuropathy (CIDP) such as Lewis\u2010Sumner syndrome (MADSAM) or a vasculitic neuropathy producing mononeuritis multiplex. In both cases, immune-mediated inflammation is the hallmark. The underlying mechanism is thought to be immune-mediated inflammation that results in demyelination and/or axonal injury confined to discrete peripheral nerves. In variants of CIDP (including Lewis\u2013Sumner syndrome) or in vasculitic processes, inflammatory cells target myelin or the vasa nervorum leading to conduction block and focal deficits. The sequential presentation \u2013 first a unilateral foot drop with later involvement (with partial recovery) and subsequent hand weakness and sensory symptoms \u2013 is typical of a patchy, multifocal distribution of nerve involvement. This differentiates it from uniformly ascending weakness seen in conditions like Guillain\u2013Barr\u00e9 syndrome and from pure motor variants such as multifocal motor neuropathy (which generally lack sensory deficits). The evaluation should begin with a detailed clinical history, followed by electrophysiologic studies (nerve conduction studies and electromyography) to document conduction block and demyelination. Laboratory evaluation for autoimmune markers and vasculitis should be performed, and in selected cases nerve biopsy is considered. Differentials include Lewis\u2013Sumner syndrome (MADSAM), vasculitic neuropathy (mononeuritis multiplex), and other forms of CIDP. For an inflammatory neuropathy that is suspected to be steroid-responsive (such as a CIDP variant or vasculitic neuropathy), the initial step in management is immunomodulation. High-dose (pulse) corticosteroids are a common first-line therapy to reduce inflammation and limit nerve injury. In patients who are pregnant or lactating, corticosteroids can be used but require counseling regarding potential side effects; alternatively, IVIG is considered a safe and effective option if steroids are contraindicated. Azathioprine (Imuran) is typically reserved as a steroid-sparing agent or for long-term maintenance therapy rather than for initial management. Option A (Imuran) is mainly used as an adjunct for long-term immunosuppression and is not typically used as initial therapy. Option B (Pulse steroid) rapidly addresses the acute inflammatory process and is appropriate for conditions like CIDP and vasculitic neuropathy. Option C (IVIG) is generally reserved for entities such as Guillain\u2013Barr\u00e9 syndrome, multifocal motor neuropathy, or when steroids are contraindicated (including in a subset of pregnant patients). Option D is not provided. Given the clinical picture with both motor and sensory involvement along with the multifocal pattern, pulse steroids are a rational initial treatment choice. \u2022 Asymmetric, multifocal deficits (especially when both motor and sensory are involved) favor diagnoses like Lewis\u2013Sumner syndrome or vasculitic neuropathy over classical symmetric polyneuropathies.  \u2022 Electrophysiologic studies are essential to confirm demyelination and to differentiate among immune neuropathies.  \u2022 In immune-mediated neuropathies, early immunotherapy (with pulse steroids or IVIG) is critical to prevent permanent nerve damage.  \u2022 Pregnancy and lactation are important considerations; both steroids and IVIG have roles depending on the clinical context and safety profile. Recent studies and consensus guidelines support the use of high-dose corticosteroids as an effective first-line treatment in steroid-responsive immune neuropathies such as CIDP variants and vasculitic neuropathy. While IVIG is an alternative\u2014especially in pure motor variants or when steroids are contraindicated\u2014current evidence indicates that pulse steroid therapy can rapidly control inflammation in appropriately selected patients. In pregnancy, both agents are considered safe when benefits outweigh the risks, with careful monitoring.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "One month old baby presented with history of one week of lethargy, weak cry and weak sucking, examination showed hypotonia, ptosis and non-reactive pupils, what is the diagnosis?",
    "option_a": "Botulism",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Infant botulism is a neuromuscular disorder caused by the colonization of an infant's immature gastrointestinal tract with Clostridium botulinum spores. The bacteria produce botulinum toxin in situ, which interferes with acetylcholine release at the neuromuscular junction, leading to a characteristic descending paralysis. The clinical presentation in a one\u2010month old with lethargy, weak cry and sucking, hypotonia, ptosis, and non-reactive pupils fits this profile. Botulinum toxin cleaves SNARE proteins required for the fusion of acetylcholine vesicles with the presynaptic membrane, thereby blocking neurotransmission at the neuromuscular and autonomic synapses. This results in muscle weakness and autonomic dysfunction, as seen with the non-reactive pupils and ptosis in this infant. The \u2018floppy baby syndrome\u2019 seen in infant botulism typically includes poor feeding, weak cry, generalized hypotonia, and cranial nerve involvement (e.g., ptosis, fixed dilated or non-reactive pupils). These clinical findings help differentiate it from other conditions causing neonatal hypotonia, such as congenital myasthenic syndromes or central nervous system disorders. Diagnosis is primarily clinical, supported by laboratory evaluation such as stool assays for botulinum toxin or cultures for C. botulinum. Differential diagnoses include congenital myasthenia gravis, neuromuscular junction disorders, sepsis, and metabolic disorders. The distinct autonomic findings (like non-reactive pupils) make botulism more likely. Management is primarily supportive and includes ensuring adequate respiratory function and nutrition. The use of Botulism Immune Globulin Intravenous (BabyBIG) is recommended in confirmed cases to neutralize circulating toxin. There are no direct pregnancy considerations because the patient is a neonate; however, if the infant is breastfed, continued breastfeeding is encouraged as it supports recovery. Protocols emphasize early recognition and supportive care to mitigate complications. Option A, Botulism, is the correct answer given the constellation of symptoms in this infant. Although the other options are not specified, they would likely pertain to conditions that do not typically present with both the neuromuscular weakness and the noted autonomic dysfunction (e.g., non-reactive pupils) seen in botulism. A key clue to infant botulism is the combination of poor feeding, generalized weakness with descending paralysis, and cranial nerve involvement (manifesting as ptosis and fixed pupils). Early supplementation with Botulism Immune Globulin can significantly improve outcomes. A careful history of environmental exposures (such as dust or honey in older infants) is also essential. Recent guidelines and studies continue to support the use of BabyBIG in the management of infant botulism along with essential supportive care. While rapid diagnostic tests are being developed, clinical diagnosis remains the cornerstone. Continued breastfeeding is advised during treatment, as it does not interfere with therapy and aids in overall recovery.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 34-year-old man had progressive difficulty climbing stairs and respiratory difficulties requiring BiPAP, what is the most likely cause?",
    "option_a": "Acid maltase deficiency",
    "option_b": "Pyruvate kinase",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The question describes a 34\u2010year\u2010old man with progressive difficulty climbing stairs and respiratory difficulties requiring BiPAP. This pattern of proximal muscle weakness with early respiratory muscle involvement is classically seen in late-onset Pompe disease, which is caused by acid maltase (acid alpha-glucosidase) deficiency. In Pompe disease, mutations in the gene coding for acid alpha-glucosidase result in a deficiency of this lysosomal enzyme. The lack of enzyme activity leads to excessive accumulation of glycogen within lysosomes of skeletal, cardiac, and smooth muscles, causing cell dysfunction and progressive muscle weakness, including the diaphragm and accessory respiratory muscles. Late-onset Pompe disease typically presents in adolescence or adulthood with slowly progressive limb-girdle muscle weakness (difficulty climbing stairs) and respiratory insufficiency. Patients may initially have minimal limb symptoms while respiratory failure becomes a predominant feature as diaphragmatic weakness progresses. Differential diagnoses include other metabolic myopathies (e.g., other glycogen storage disorders), limb-girdle muscular dystrophies, and inflammatory myopathies. Diagnostic work-up involves measuring acid alpha-glucosidase activity in blood or tissue, genetic testing to confirm mutations, electromyography (EMG) to assess myopathic changes, and muscle biopsy, which may reveal glycogen accumulation in lysosomes. Management of late-onset Pompe disease includes enzyme replacement therapy (ERT) with alglucosidase alfa, which has been shown to slow disease progression and improve muscle strength and respiratory function. Supportive care involves physical therapy and respiratory support, including non-invasive ventilation (e.g., BiPAP) as needed. In pregnancy and lactation, a careful risk-benefit analysis should be undertaken when considering ERT; current guidelines suggest that while data are limited, treatment may be continued if the maternal condition warrants it, under the close supervision of multidisciplinary specialists. Option A (Acid maltase deficiency) corresponds to Pompe disease, fitting the clinical picture described. Option B (Pyruvate kinase deficiency) causes hemolytic anemia rather than a myopathic process, making it an incorrect choice. Although options C and D are not specified, they do not align with the classic presentation of progressive proximal weakness with respiratory compromise seen in Pompe disease. Late-onset Pompe disease should be suspected in patients with unexplained proximal muscle weakness combined with respiratory insufficiency. Early recognition and initiation of ERT can improve outcomes. Respiratory involvement may be disproportionate to the degree of limb weakness, underscoring the need for pulmonary evaluation. Recent clinical trials and longitudinal studies have indicated that early enzyme replacement therapy in Pompe disease improves motor and respiratory outcomes. Ongoing research continues to focus on optimizing dosing regimens and evaluating long-term benefits, including in special populations such as pregnant or lactating women, where individualized treatment decisions remain paramount.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with weakness symptoms suggestive of (Anti- Musk MG) was on Mycophenolic acid and steroid with no benefit switched to Azathioprine and developed hepatotoxicity, what to give?",
    "option_a": "Rituximab infusion",
    "option_b": "Monthly IVIG",
    "option_c": "3,4 Dalfampridine",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-MuSK myasthenia gravis is a subtype of myasthenia gravis where autoantibodies are directed against muscle-specific kinase (MuSK), an essential protein for maintaining acetylcholine receptor clusters at the neuromuscular junction. This variant often has a different clinical profile and treatment response compared to anti-AChR myasthenia gravis. In anti-MuSK MG, antibodies disrupt the normal function of MuSK, impairing the maintenance and clustering of acetylcholine receptors at the postsynaptic membrane. This leads to inefficient neuromuscular transmission and muscle weakness. Refractory cases may not respond well to traditional immunosuppressants, and toxicity (such as hepatotoxicity with azathioprine) can further limit options. Rituximab, a monoclonal antibody targeting CD20+ B cells, helps decrease the production of pathogenic antibodies. Patients often present with prominent bulbar and respiratory muscle involvement, with weakness that might not respond predictably to acetylcholinesterase inhibitors. Failure to improve on first\u2010line agents (steroids, mycophenolic acid, or azathioprine with associated toxicity) makes alternative therapies like rituximab an attractive option. Diagnosis is confirmed by detecting anti-MuSK antibodies. Differential diagnoses include anti-AChR positive myasthenia gravis, congenital myasthenic syndromes, and other neuromuscular junction disorders. Electrophysiological tests such as repetitive nerve stimulation and single-fiber EMG can aid in diagnosis. First-line treatments typically include corticosteroids combined with immunosuppressants (mycophenolate mofetil, azathioprine). In patients refractory to these treatments or where hepatotoxicity is a concern, rituximab is recommended as a second-line treatment based on current clinical guidelines. Rituximab is particularly effective in anti-MuSK MG, though its use in pregnant or lactating women requires careful risk\u2013benefit analysis due to potential fetal/neonatal immunosuppression; alternative management or postponing therapy until after lactation may be considered. Option A (Rituximab infusion) is correct because it targets the B cells producing the pathogenic anti-MuSK antibodies. Option B (Monthly IVIG) is used mainly in crises or as a short\u2010term bridge rather than for long\u2010term disease control. Option C (3,4 Dalfampridine) is indicated for symptomatic treatment in conditions like multiple sclerosis and does not address the underlying immune dysfunction in MG. 1. Anti-MuSK MG often presents with severe bulbar and respiratory muscle involvement and may not respond to acetylcholinesterase inhibitors. 2. Rituximab has emerged as an effective therapy for refractory anti-MuSK MG, especially when other immunosuppressants are contraindicated or poorly tolerated. Recent studies and updated guidelines support the use of rituximab in anti-MuSK MG as an effective treatment option in refractory cases. Ongoing research is focused on individualized immunotherapy approaches and the long-term safety profile of rituximab in this patient population.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with back pain, facial sweating and intermittent epigastric pain associated with progressive distal sensory loss and weakness, what is the diagnosis?",
    "option_a": "Acute inflammatory demyelinating polyneuropathy",
    "option_b": "acute intermittent porphyria",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Acute intermittent porphyria (AIP) is a metabolic disorder of heme synthesis caused by a deficiency in the enzyme porphobilinogen deaminase. It is characterized by neurovisceral symptoms with a combination of abdominal pain, autonomic instability, and neurological manifestations. In AIP, triggers such as certain drugs, stress, or hormonal changes lead to the accumulation of porphyrin precursors (e.g., aminolevulinic acid and porphobilinogen) which are neurotoxic. Their excess causes a spectrum of symptoms including severe abdominal pain, autonomic dysfunction (like sweating), and neuropathy, which may present as progressive motor and sometimes sensory impairment. The clinical picture of back pain, facial sweating (reflecting autonomic involvement), and intermittent epigastric pain strongly suggests an acute porphyric attack. The progressive distal sensory loss and weakness can also be seen in porphyric neuropathy, which may sometimes mimic other neuromuscular conditions but is distinguished by the combination of visceral symptoms and neuropathy. Differential diagnoses include Guillain-Barr\u00e9 syndrome (AIDP), which typically presents with ascending weakness without notable abdominal pain, and other metabolic or toxic neuropathies. Diagnosis of AIP is confirmed by elevated urinary porphobilinogen (PBG) levels, often with urine that darkens on standing. During acute attacks, the first-line treatment is intravenous hemin, which works by downregulating aminolevulinic acid synthase, thereby reducing the production of toxic porphyrin precursors. Supportive care (hydration, analgesia, and correction of electrolyte imbalances) is also crucial. In pregnancy, IV hemin can be used with caution while balancing maternal benefits and potential fetal risks; avoidance of triggering factors is equally important. Option B (Acute intermittent porphyria) is correct because the presence of visceral pain (epigastric pain), autonomic dysfunction (facial sweating), and neuropathic symptoms fits this diagnosis. Option A (Acute inflammatory demyelinating polyneuropathy) primarily involves progressive motor weakness with areflexia and lacks the characteristic abdominal pain and autonomic symptoms seen in AIP. 1. Acute attacks of AIP are often precipitated by medications, fasting, or stress and present with severe abdominal pain plus neurological deficits. 2. AIP should be suspected in patients with unexplained gastrointestinal symptoms accompanied by neuropathic features and autonomic instability. Recent guidelines emphasize early diagnosis and prompt treatment with IV hemin during acute AIP attacks. Ongoing research is assessing novel therapies and gene-based approaches to reduce the frequency and severity of attacks.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Case of Kennedy disease (imbalance, muscle cramps and perioral fasciculation, proximal weakness, bulbar weakness, shin twitching, no mention of gynecomastia), what will be found on genetic test?",
    "option_a": "CTG",
    "option_b": "GAA",
    "option_c": "CGG",
    "option_d": "CAG",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Kennedy disease, also known as spinobulbar muscular atrophy, is an X-linked disorder caused by a trinucleotide repeat expansion in the androgen receptor gene. It primarily affects motor neurons leading to progressive weakness and fasciculations. The disease is due to an abnormal expansion of CAG trinucleotide repeats in the androgen receptor gene, resulting in a polyglutamine tract expansion. This abnormal protein misfolds and aggregates, leading to toxicity and degeneration of lower motor neurons. Although gynecomastia is a common feature due to androgen receptor dysfunction, it may not always be present. Patients typically present in adulthood with symptoms including muscle cramps, fasciculations (often perioral), proximal muscle weakness, and bulbar signs such as dysarthria or dysphagia. The presence of limb and bulbar involvement, even in the absence of gynecomastia, should raise suspicion for Kennedy disease. The diagnostic gold standard is genetic testing, which reveals an abnormal CAG repeat expansion in the androgen receptor gene. Differential diagnoses include amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, but the pattern of bulbar involvement with endocrine signs helps differentiate Kennedy disease. There is currently no cure for Kennedy disease; management is primarily supportive and includes physical therapy, symptomatic treatment for muscle cramps, and speech therapy for bulbar symptoms. Genetic counseling is essential. In pregnant or lactating carriers, counseling is particularly important for family planning, although direct treatment modifications are not applicable as no disease-modifying treatments exist. Option D (CAG expansion) is correct as Kennedy disease is due to an expanded CAG trinucleotide repeat in the androgen receptor gene. Option A (CTG) is associated with myotonic dystrophy, Option B (GAA) is seen in Friedreich ataxia, and Option C (CGG) is related to Fragile X syndrome. 1. Kennedy disease typically affects adult males and presents with a combination of motor neuron signs and subtle endocrine abnormalities. 2. The definitive diagnosis is made by identifying a CAG repeat expansion in the androgen receptor gene via genetic testing. Current research is exploring gene-silencing and molecular approaches to target the underlying genetic defect in Kennedy disease. However, as of now, management remains symptomatic and supportive, with ongoing clinical trials investigating potential disease-modifying therapies.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggestive of Botulism, what is the pathophysiology responsible?",
    "option_a": "Irreversible blockage of presynaptic ACH receptor",
    "option_b": "Irreversible blockage of postsynaptic ACH receptor",
    "option_c": "Irreversible blockage of protein that is responsible for acetylcholine release",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Botulism is a neuroparalytic illness caused by toxins produced by Clostridium botulinum. The core defect is due to the inhibition of acetylcholine release at neuromuscular junctions, leading to descending paralysis. Botulinum toxin binds to presynaptic nerve terminals and internalizes, where it cleaves SNARE proteins (such as SNAP-25, syntaxin, or synaptobrevin). This cleavage prevents the vesicle-mediated release of acetylcholine into the neuromuscular junction. The blockage is essentially irreversible until new SNARE proteins are synthesized, resulting in sustained weakness. Clinically, patients develop a symmetric descending flaccid paralysis accompanied by bulbar dysfunction. Early symptoms can include blurred vision, dry mouth, and difficulty swallowing. Autonomic signs might also appear but the key feature is the failure to release acetylcholine, leading to neuromuscular blockade. Diagnosis is largely clinical, supported by a history of exposure and characteristic symptoms. Differential diagnoses include Guillain-Barr\u00e9 syndrome and myasthenia gravis, which can be differentiated by their clinical course, pattern of paralysis, and specific diagnostic tests (e.g., nerve conduction studies, antibody tests). The mainstay of treatment is the administration of antitoxin as early as possible to neutralize circulating toxin, along with supportive care (including respiratory support if needed). In pregnant or lactating women, the same antitoxin is used when indicated because the risk of severe maternal disease outweighs potential risks. Intensive care monitoring is crucial until recovery occurs as new SNARE proteins replace the cleaved ones. Option C (Irreversible blockage of protein that is responsible for acetylcholine release) is correct because botulinum toxin impairs neuromuscular transmission by cleaving SNARE proteins, thus preventing the release of acetylcholine. Option A and Option B incorrectly implicate direct receptor blockade rather than interference with the release mechanism. 1. Botulism characteristically produces a descending paralysis with prominent bulbar and respiratory involvement. 2. Early administration of antitoxin is critical to reduce morbidity and mortality associated with botulism. Recent evidence underscores the importance of early recognition and antitoxin administration in improving outcomes for botulism. Research continues on novel therapeutic strategies to enhance recovery and on improved formulations of antitoxin that can be used safely in all populations, including pregnancy.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young boy went for a football match with his friends, later he started to have proximal muscle weakness, and his urine turned brown, he was admitted to the hospital CK is high. Upon review of his chart, you noticed that he was admitted last year with same presentation. What is the defected enzyme?",
    "option_a": "Acid fast Maltese",
    "option_b": "Carnitine palmitoyltransferase II deficiency",
    "option_c": "myophosphorylase deficiency",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a young boy with recurrent episodes of exercise\u2010induced muscle weakness accompanied by brown urine (myoglobinuria) and high CK levels. These findings are characteristic of a metabolic myopathy, most notably McArdle disease, which is due to a deficiency of the enzyme myophosphorylase (muscle glycogen phosphorylase). In McArdle disease (Glycogen Storage Disease Type V), a mutation in the PYGM gene leads to defective myophosphorylase, an enzyme essential for glycogenolysis in skeletal muscle. The inability to break down glycogen into glucose-1-phosphate during strenuous exercise results in an energy deficit, muscle fiber necrosis, and release of myoglobin into the circulation. This explains the dark (\u2018brown\u2019) urine and elevated CK due to muscle breakdown. Patients typically present during adolescence or early adulthood with exercise intolerance, muscle cramps, pain, and episodes of myoglobinuria, often after short, strenuous activities (such as playing football). A unique clinical clue is the 'second wind' phenomenon, where symptoms improve after a brief rest as alternative energy sources are mobilized. The workup involves a careful clinical history and physical exam. Key diagnostic evaluations include: 1) the ischemic forearm exercise test, which typically shows a flat lactate curve, 2) measurement of CK levels (usually elevated), and 3) confirmatory muscle biopsy with histochemical staining to demonstrate reduced or absent myophosphorylase activity \u2014 with genetic testing (for PYGM mutations) increasingly used for confirmation. Differential diagnoses include fatty acid oxidation disorders (e.g., CPT II deficiency) which usually have different triggers (e.g. prolonged exercise, fasting) and Pompe disease (acid maltase deficiency), which has an infantile onset with cardiomyopathy. Management is primarily supportive. First-line strategies include patient education to avoid strenuous activities and to modify exercise regimens toward moderate aerobic exercise that may invoke the 'second wind' phenomenon. Nutritional management (high-carbohydrate diet) before exercise is also recommended. There is no established enzyme replacement therapy. Pregnancy and lactation considerations involve advising affected females to maintain moderate activity levels and proper nutrition, with careful monitoring to avoid rhabdomyolysis. Option A (Acid fast Maltese) seems to be a misnomer likely referring to acid maltase deficiency, which causes Pompe disease rather than exercise-induced rhabdomyolysis in a young individual. Option B (Carnitine palmitoyltransferase II deficiency) is an acquired defect of fatty acid oxidation that generally presents in later childhood or adulthood with exercise-induced rhabdomyolysis but has distinct triggering factors (prolonged exercise or fasting) and different biochemical findings. Option C (myophosphorylase deficiency) is the correct answer as it directly corresponds to McArdle disease. \u2022 The classic 'second wind' phenomenon is a high-yield clue to McArdle disease.  \u2022 Elevated CK and recurrent myoglobinuria following exercise are key features.  \u2022 Always differentiate between glycolytic pathway defects (McArdle) and fatty acid oxidation disorders (such as CPT II deficiency). Recent advances emphasize the importance of genetic testing for definitive diagnosis and the role of tailored, supervised exercise programs in improving quality of life. Current guidelines continue to recommend supportive management with dietary and exercise modifications, as no curative treatment is available.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with dysphasia and dysarthria and proximal muscle weakness, found to have anti-Musk antibody, what you will find?",
    "option_a": "Normal thymus",
    "option_b": "Associated with HLA DRB8",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a young boy with recurrent episodes of exercise\u2010induced muscle weakness accompanied by brown urine (myoglobinuria) and high CK levels. These findings are characteristic of a metabolic myopathy, most notably McArdle disease, which is due to a deficiency of the enzyme myophosphorylase (muscle glycogen phosphorylase). In McArdle disease (Glycogen Storage Disease Type V), a mutation in the PYGM gene leads to defective myophosphorylase, an enzyme essential for glycogenolysis in skeletal muscle. The inability to break down glycogen into glucose-1-phosphate during strenuous exercise results in an energy deficit, muscle fiber necrosis, and release of myoglobin into the circulation. This explains the dark (\u2018brown\u2019) urine and elevated CK due to muscle breakdown. Patients typically present during adolescence or early adulthood with exercise intolerance, muscle cramps, pain, and episodes of myoglobinuria, often after short, strenuous activities (such as playing football). A unique clinical clue is the 'second wind' phenomenon, where symptoms improve after a brief rest as alternative energy sources are mobilized. The workup involves a careful clinical history and physical exam. Key diagnostic evaluations include: 1) the ischemic forearm exercise test, which typically shows a flat lactate curve, 2) measurement of CK levels (usually elevated), and 3) confirmatory muscle biopsy with histochemical staining to demonstrate reduced or absent myophosphorylase activity \u2014 with genetic testing (for PYGM mutations) increasingly used for confirmation. Differential diagnoses include fatty acid oxidation disorders (e.g., CPT II deficiency) which usually have different triggers (e.g. prolonged exercise, fasting) and Pompe disease (acid maltase deficiency), which has an infantile onset with cardiomyopathy. Management is primarily supportive. First-line strategies include patient education to avoid strenuous activities and to modify exercise regimens toward moderate aerobic exercise that may invoke the 'second wind' phenomenon. Nutritional management (high-carbohydrate diet) before exercise is also recommended. There is no established enzyme replacement therapy. Pregnancy and lactation considerations involve advising affected females to maintain moderate activity levels and proper nutrition, with careful monitoring to avoid rhabdomyolysis. Option A (Acid fast Maltese) seems to be a misnomer likely referring to acid maltase deficiency, which causes Pompe disease rather than exercise-induced rhabdomyolysis in a young individual. Option B (Carnitine palmitoyltransferase II deficiency) is an acquired defect of fatty acid oxidation that generally presents in later childhood or adulthood with exercise-induced rhabdomyolysis but has distinct triggering factors (prolonged exercise or fasting) and different biochemical findings. Option C (myophosphorylase deficiency) is the correct answer as it directly corresponds to McArdle disease. \u2022 The classic 'second wind' phenomenon is a high-yield clue to McArdle disease.  \u2022 Elevated CK and recurrent myoglobinuria following exercise are key features.  \u2022 Always differentiate between glycolytic pathway defects (McArdle) and fatty acid oxidation disorders (such as CPT II deficiency). Recent advances emphasize the importance of genetic testing for definitive diagnosis and the role of tailored, supervised exercise programs in improving quality of life. Current guidelines continue to recommend supportive management with dietary and exercise modifications, as no curative treatment is available.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young patient had recurrent weakness induced by exercise that improves after a period of rest, how to reach the diagnosis (Case of McArdle disease)",
    "option_a": "Fibroblast culture with enzyme microarray",
    "option_b": "Acid maltase profile",
    "option_c": "Acyl carnitine profile",
    "option_d": "Something pyruvate kinase",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a young boy with recurrent episodes of exercise\u2010induced muscle weakness accompanied by brown urine (myoglobinuria) and high CK levels. These findings are characteristic of a metabolic myopathy, most notably McArdle disease, which is due to a deficiency of the enzyme myophosphorylase (muscle glycogen phosphorylase). In McArdle disease (Glycogen Storage Disease Type V), a mutation in the PYGM gene leads to defective myophosphorylase, an enzyme essential for glycogenolysis in skeletal muscle. The inability to break down glycogen into glucose-1-phosphate during strenuous exercise results in an energy deficit, muscle fiber necrosis, and release of myoglobin into the circulation. This explains the dark (\u2018brown\u2019) urine and elevated CK due to muscle breakdown. Patients typically present during adolescence or early adulthood with exercise intolerance, muscle cramps, pain, and episodes of myoglobinuria, often after short, strenuous activities (such as playing football). A unique clinical clue is the 'second wind' phenomenon, where symptoms improve after a brief rest as alternative energy sources are mobilized. The workup involves a careful clinical history and physical exam. Key diagnostic evaluations include: 1) the ischemic forearm exercise test, which typically shows a flat lactate curve, 2) measurement of CK levels (usually elevated), and 3) confirmatory muscle biopsy with histochemical staining to demonstrate reduced or absent myophosphorylase activity \u2014 with genetic testing (for PYGM mutations) increasingly used for confirmation. Differential diagnoses include fatty acid oxidation disorders (e.g., CPT II deficiency) which usually have different triggers (e.g. prolonged exercise, fasting) and Pompe disease (acid maltase deficiency), which has an infantile onset with cardiomyopathy. Management is primarily supportive. First-line strategies include patient education to avoid strenuous activities and to modify exercise regimens toward moderate aerobic exercise that may invoke the 'second wind' phenomenon. Nutritional management (high-carbohydrate diet) before exercise is also recommended. There is no established enzyme replacement therapy. Pregnancy and lactation considerations involve advising affected females to maintain moderate activity levels and proper nutrition, with careful monitoring to avoid rhabdomyolysis. Option A (Acid fast Maltese) seems to be a misnomer likely referring to acid maltase deficiency, which causes Pompe disease rather than exercise-induced rhabdomyolysis in a young individual. Option B (Carnitine palmitoyltransferase II deficiency) is an acquired defect of fatty acid oxidation that generally presents in later childhood or adulthood with exercise-induced rhabdomyolysis but has distinct triggering factors (prolonged exercise or fasting) and different biochemical findings. Option C (myophosphorylase deficiency) is the correct answer as it directly corresponds to McArdle disease. \u2022 The classic 'second wind' phenomenon is a high-yield clue to McArdle disease.  \u2022 Elevated CK and recurrent myoglobinuria following exercise are key features.  \u2022 Always differentiate between glycolytic pathway defects (McArdle) and fatty acid oxidation disorders (such as CPT II deficiency). Recent advances emphasize the importance of genetic testing for definitive diagnosis and the role of tailored, supervised exercise programs in improving quality of life. Current guidelines continue to recommend supportive management with dietary and exercise modifications, as no curative treatment is available.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 40-year-old man, had RTA and right Acetabular fracture, developed right ankle dorsiflexion weakness, decrease sensation over dorsum of the right foot. What structure is most likely affected?",
    "option_a": "Lateral portion of sciatic nerve",
    "option_b": "Medial portion of sciatic nerve",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario describes a patient with foot drop (ankle dorsiflexion weakness) and numbness over the dorsum of the foot following a traumatic acetabular fracture. This is most consistent with an injury to the lateral portion of the sciatic nerve, which corresponds to the common peroneal nerve that supplies motor innervation to the dorsiflexors of the foot and provides sensory innervation to the dorsum of the foot. Traumatic mechanisms such as an acetabular fracture can cause direct compression, stretching, or contusion injuries to the sciatic nerve. The lateral division (common peroneal nerve) is particularly vulnerable due to its relatively fixed position and less protective connective tissue support compared to the medial (tibial) component. Injury to this nerve leads to impaired transmission of motor signals to the muscles responsible for dorsiflexion and to the sensory fibers innervating the dorsal foot. Patients with common peroneal nerve injury typically present with foot drop (inability to dorsiflex the ankle), tripping, and loss of sensation over the dorsum of the foot. This clinical picture clearly correlates with the pathway of the lateral division of the sciatic nerve. Diagnosis involves a detailed neurological examination, focusing on motor strength and sensory deficits. Differential diagnoses include lumbar radiculopathies (especially L4-L5 nerve roots), isolated common peroneal nerve injuries at the fibular head, or compartment syndrome. Electrophysiological studies (nerve conduction studies and electromyography) may be utilized to confirm the location and extent of the nerve injury. Management includes initial conservative treatment with physiotherapy, splinting/ankle-foot orthoses to prevent falls, and pain management. Serial neurological examinations and electrodiagnostic studies may guide further treatment. In cases where there is no recovery over several months or when there is evidence of nerve transection, surgical exploration may be considered. In pregnancy and lactation, conservative management remains the mainstay with special attention to the safety profile of medications (avoiding teratogenic drugs) and modifications in surgical approaches if intervention becomes necessary. Option A (Lateral portion of the sciatic nerve) correctly identifies the part of the nerve responsible for dorsiflexion and sensation over the dorsum of the foot. Option B (Medial portion of the sciatic nerve) would primarily affect plantar flexion and the sensation of the sole, which does not match the patient's deficits. The remaining options (C and D) are absent, making Option A the most appropriate and best-supported answer. \u2022 The common peroneal nerve (lateral division of the sciatic nerve) is particularly susceptible to injury in pelvic or acetabular fractures.\n\u2022 Foot drop with sensory deficits over the dorsum of the foot is a classic presentation of common peroneal nerve injury.\n\u2022 Early neurophysiological studies are crucial for assessing nerve continuity and planning further management. Recent guidelines support early and accurate neurologic assessment in peripheral nerve injuries to determine the prognosis and the necessity of surgical intervention. Conservative management is first-line, and surgical repair is reserved for cases with nerve discontinuity or lack of functional improvement after several months. In patients needing intervention during pregnancy or lactation, careful selection of imaging modalities and medications that are safe in these populations is essential.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Infant with Hypotonia, macroglossia, feeding problems, trouble breathing, muscle weakness, enlarged heart, what the defected enzyme?",
    "option_a": "Acid fast Maltese",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This infant\u2019s presentation \u2013 hypotonia, macroglossia, feeding and respiratory difficulties, muscle weakness, and an enlarged heart \u2013 is the classic clinical picture of Pompe disease (Glycogen Storage Disease Type II). Pompe disease is caused by a deficiency in acid alpha\u2010glucosidase, formerly called acid maltase. Acid alpha\u2010glucosidase is a lysosomal enzyme that degrades glycogen. Its deficiency results in the accumulation of glycogen in lysosomes, especially in cardiac and skeletal muscle cells, leading to cellular dysfunction. In the infantile form the accumulation is marked and leads to severe cardiomyopathy and muscle weakness, with death often occurring within the first year if untreated. The infantile form of Pompe disease presents with severe muscle hypotonia, feeding difficulties, macroglossia, and cardiomegaly (enlarged heart), which leads to respiratory difficulties. These features correlate with the widespread glycogen deposition in muscles and the heart. Diagnosis is generally confirmed by demonstrating low acid alpha\u2010glucosidase activity. This can be done via enzyme assays in blood (e.g., dried blood spot), muscle biopsy, or cultured fibroblasts along with genetic testing for mutations in the GAA gene. Differential diagnoses include other neuromuscular disorders in infancy but the presence of cardiomyopathy is key to suspecting Pompe disease. The cornerstone of management is Enzyme Replacement Therapy (ERT) with alglucosidase alfa, which has been shown to improve cardiac function and prolong survival if started early. Supportive care is essential and includes respiratory support, nutritional management, and physical therapy. In the context of pregnancy and lactation, there are limited data on ERT safety; treatment decisions should be individualized with risk\u2013benefit discussions and multidisciplinary consultation. Option A, despite the unusual wording 'Acid fast Maltese', is understood here to refer to 'acid maltase deficiency', which is another name for acid alpha\u2010glucosidase deficiency \u2013 the defect in Pompe disease. The other options were not provided, but with the clinical picture the enzyme deficiency implicated is clearly that of Pompe disease. 1. Infantile Pompe disease is the only glycogen storage disease that involves a significant cardiomyopathy in early life. 2. Early diagnosis and prompt initiation of ERT are key to improving survival and quality of life. Recent studies and guidelines emphasize early screening and treatment with ERT. Research is also underway on gene therapy and novel chaperone molecules to improve enzyme function, underlining the importance of early and precise diagnosis.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Child presented with proximal muscle weakness, he was diagnosed Laminopathy (or LMNA mutation) based on genetic test, what is expected to be seen in examination?",
    "option_a": "Elbow and ankle contractions",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This infant\u2019s presentation \u2013 hypotonia, macroglossia, feeding and respiratory difficulties, muscle weakness, and an enlarged heart \u2013 is the classic clinical picture of Pompe disease (Glycogen Storage Disease Type II). Pompe disease is caused by a deficiency in acid alpha\u2010glucosidase, formerly called acid maltase. Acid alpha\u2010glucosidase is a lysosomal enzyme that degrades glycogen. Its deficiency results in the accumulation of glycogen in lysosomes, especially in cardiac and skeletal muscle cells, leading to cellular dysfunction. In the infantile form the accumulation is marked and leads to severe cardiomyopathy and muscle weakness, with death often occurring within the first year if untreated. The infantile form of Pompe disease presents with severe muscle hypotonia, feeding difficulties, macroglossia, and cardiomegaly (enlarged heart), which leads to respiratory difficulties. These features correlate with the widespread glycogen deposition in muscles and the heart. Diagnosis is generally confirmed by demonstrating low acid alpha\u2010glucosidase activity. This can be done via enzyme assays in blood (e.g., dried blood spot), muscle biopsy, or cultured fibroblasts along with genetic testing for mutations in the GAA gene. Differential diagnoses include other neuromuscular disorders in infancy but the presence of cardiomyopathy is key to suspecting Pompe disease. The cornerstone of management is Enzyme Replacement Therapy (ERT) with alglucosidase alfa, which has been shown to improve cardiac function and prolong survival if started early. Supportive care is essential and includes respiratory support, nutritional management, and physical therapy. In the context of pregnancy and lactation, there are limited data on ERT safety; treatment decisions should be individualized with risk\u2013benefit discussions and multidisciplinary consultation. Option A, despite the unusual wording 'Acid fast Maltese', is understood here to refer to 'acid maltase deficiency', which is another name for acid alpha\u2010glucosidase deficiency \u2013 the defect in Pompe disease. The other options were not provided, but with the clinical picture the enzyme deficiency implicated is clearly that of Pompe disease. 1. Infantile Pompe disease is the only glycogen storage disease that involves a significant cardiomyopathy in early life. 2. Early diagnosis and prompt initiation of ERT are key to improving survival and quality of life. Recent studies and guidelines emphasize early screening and treatment with ERT. Research is also underway on gene therapy and novel chaperone molecules to improve enzyme function, underlining the importance of early and precise diagnosis.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young boy went for a football match with his friends, later, he started to have proximal muscle weakness, and his urine turned brown, he had history of similar symptoms during his pervious admission, what is the defected enzyme?",
    "option_a": "Myophosphorylase deficiency",
    "option_b": "Carnitine palmitoyltransferase II deficiency",
    "option_c": "Acid maltase deficiency",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This infant\u2019s presentation \u2013 hypotonia, macroglossia, feeding and respiratory difficulties, muscle weakness, and an enlarged heart \u2013 is the classic clinical picture of Pompe disease (Glycogen Storage Disease Type II). Pompe disease is caused by a deficiency in acid alpha\u2010glucosidase, formerly called acid maltase. Acid alpha\u2010glucosidase is a lysosomal enzyme that degrades glycogen. Its deficiency results in the accumulation of glycogen in lysosomes, especially in cardiac and skeletal muscle cells, leading to cellular dysfunction. In the infantile form the accumulation is marked and leads to severe cardiomyopathy and muscle weakness, with death often occurring within the first year if untreated. The infantile form of Pompe disease presents with severe muscle hypotonia, feeding difficulties, macroglossia, and cardiomegaly (enlarged heart), which leads to respiratory difficulties. These features correlate with the widespread glycogen deposition in muscles and the heart. Diagnosis is generally confirmed by demonstrating low acid alpha\u2010glucosidase activity. This can be done via enzyme assays in blood (e.g., dried blood spot), muscle biopsy, or cultured fibroblasts along with genetic testing for mutations in the GAA gene. Differential diagnoses include other neuromuscular disorders in infancy but the presence of cardiomyopathy is key to suspecting Pompe disease. The cornerstone of management is Enzyme Replacement Therapy (ERT) with alglucosidase alfa, which has been shown to improve cardiac function and prolong survival if started early. Supportive care is essential and includes respiratory support, nutritional management, and physical therapy. In the context of pregnancy and lactation, there are limited data on ERT safety; treatment decisions should be individualized with risk\u2013benefit discussions and multidisciplinary consultation. Option A, despite the unusual wording 'Acid fast Maltese', is understood here to refer to 'acid maltase deficiency', which is another name for acid alpha\u2010glucosidase deficiency \u2013 the defect in Pompe disease. The other options were not provided, but with the clinical picture the enzyme deficiency implicated is clearly that of Pompe disease. 1. Infantile Pompe disease is the only glycogen storage disease that involves a significant cardiomyopathy in early life. 2. Early diagnosis and prompt initiation of ERT are key to improving survival and quality of life. Recent studies and guidelines emphasize early screening and treatment with ERT. Research is also underway on gene therapy and novel chaperone molecules to improve enzyme function, underlining the importance of early and precise diagnosis.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young boy with recurrent weakness after exercise, improves with period the rest, how to reach diagnosis? (Case of McArdle\u2019s disease)",
    "option_a": "Culture of Fibroblast and enzyme assay",
    "option_b": "Acid maltase profile",
    "option_c": "Acyl carnitine profile",
    "option_d": "? Something pyruvate",
    "option_e": "? Phosphofructokinase",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "McArdle\u2019s disease (Glycogen Storage Disease type V) is a metabolic myopathy resulting from a deficiency in myophosphorylase (muscle glycogen phosphorylase). This enzyme normally catalyzes the breakdown of glycogen to glucose\u20101\u2010phosphate in muscle during exercise. Its deficiency leads to a failure to mobilize glycogen for anaerobic glycolysis, causing exercise-induced muscle pain and cramps. The classic 'second wind' phenomenon occurs when blood-borne fuels temporarily compensate for the block. Due to the lack of myophosphorylase activity, patients cannot effectively break down intramuscular glycogen. During exercise, this prevents the normal production of pyruvate (and consequently lactate) via anaerobic glycolysis. In a normal individual, the ischemic forearm exercise test would elicit a rise in lactate (and pyruvate) levels; in McArdle\u2019s disease, this increase is blunted or absent. Typically, a young patient (often male) presents with recurrent episodes of exercise-induced muscle weakness, pain, and sometimes myoglobinuria. The improvement in symptoms after a short rest \u2013 the so-called 'second wind' \u2013 is a hallmark of McArdle\u2019s disease and helps distinguish it from other metabolic myopathies. The screening test is usually the ischemic forearm exercise test, where the failure to produce an adequate rise in lactate (and by extension, pyruvate) supports the diagnosis. The definitive diagnostic method is a muscle biopsy with histochemical staining and enzyme assay for myophosphorylase activity or genetic testing for PYGM gene mutations. Management is largely supportive. Patients are advised to avoid strenuous, high\u2010intensity exercise and to adopt moderate aerobic exercise, which may help improve oxidative capacity. Pre\u2010exercise carbohydrate consumption can help optimize available plasma glucose. In pregnancy and lactation, similar principles apply: exercise recommendations should be adapted to avoid undue muscle strain while ensuring maternal and fetal well\u2010being, and carbohydrate nutritional support is appropriate. Option A (Culture of Fibroblast and enzyme assay) is inappropriate because fibroblasts do not express the muscle isoform of glycogen phosphorylase. Option B (Acid maltase profile) is used in Pompe disease (GSD II), not McArdle\u2019s. Option C (Acyl carnitine profile) evaluates fatty acid oxidation disorders such as CPT-II deficiency. Option E (Phosphofructokinase) is related to Tarui disease (GSD VII), which, although it also produces exercise intolerance, has distinctive features including hemolysis. Option D, despite its imprecise wording (\u2018something pyruvate\u2019), is intended to refer to a diagnostic strategy that hinges on the measurement of glycolytic end-products \u2013 specifically, the absence (or severely blunted rise) of pyruvate (and lactate) following exercise. This flat response on the forearm exercise test is characteristic of McArdle\u2019s disease, making Option D the best choice among those provided. \u2022 The 'second wind' phenomenon is a key clue to McArdle\u2019s disease.  \u2022 An absent rise in lactate (or glycolytic intermediates such as pyruvate) during the ischemic forearm exercise test is highly suggestive of the disorder.  \u2022 Muscle biopsy and genetic testing provide definitive confirmation. Recent clinical guidelines continue to endorse the use of the forearm exercise test as an initial, noninvasive screening modality in suspected cases of McArdle\u2019s disease. Confirmatory diagnosis via muscle biopsy with enzyme assay\u2014and more recently, PYGM gene mutation analysis\u2014remains the gold standard. Management continues to focus on lifestyle modifications and tailored exercise counseling, with special adjustments recommended during pregnancy and lactation to ensure safety and effective energy utilization.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]